Your browser doesn't support javascript.
loading
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Metro, Giulio; Addeo, Alfredo; Signorelli, Diego; Gili, Alessio; Economopoulou, Panagiota; Roila, Fausto; Banna, Giuseppe; De Toma, Alessandro; Rey Cobo, Juliana; Camerini, Andrea; Christopoulou, Athina; Lo Russo, Giuseppe; Banini, Marco; Galetta, Domenico; Jimenez, Beatriz; Collazo-Lorduy, Ana; Calles, Antonio; Baxevanos, Panagiotis; Linardou, Helena; Kosmidis, Paris; Garassino, Marina C; Mountzios, Giannis.
Affiliation
  • Metro G; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
  • Addeo A; Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
  • Signorelli D; Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, Italy.
  • Gili A; Public Health Section, Department of Experimental Medicine, University of Perugia, Perugia, Italy.
  • Economopoulou P; Oncology Department, Attikon University Hospital, Athens, Greece.
  • Roila F; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
  • Banna G; Medical Oncology, Ospedale Cannizzaro, Catania, Italy.
  • De Toma A; Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, Italy.
  • Rey Cobo J; Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
  • Camerini A; U.O.C. Oncologia, Ospedale Versilia, Lido di Camaiore (LU), Italy.
  • Christopoulou A; Medical Oncology, Agios Andreas General Hospital of Patras, Patras, Greece.
  • Lo Russo G; Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, Italy.
  • Banini M; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
  • Galetta D; Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Jimenez B; Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Collazo-Lorduy A; Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Calles A; Division of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Baxevanos P; Second Department of Medical Oncology, Saint Savvas Anti-Cancer Hospital, Athens, Greece.
  • Linardou H; First Department of Medical Oncology, Metropolitan Hospital, Athens, Greece.
  • Kosmidis P; Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
  • Garassino MC; Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, Italy.
  • Mountzios G; Second Department of Medical Oncology, Henry Dunant Hospital Center, Athens, Greece.
J Thorac Dis ; 11(12): 4972-4981, 2019 Dec.
Article in En | MEDLINE | ID: mdl-32030213
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Risk_factors_studies Language: En Journal: J Thorac Dis Year: 2019 Type: Article Affiliation country: Italy
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Risk_factors_studies Language: En Journal: J Thorac Dis Year: 2019 Type: Article Affiliation country: Italy